<DOC>
	<DOC>NCT02802228</DOC>
	<brief_summary>This placebo-controlled study will assess the safety and efficacy of a 90-day course of treatment with ifetroban for portal hypertension in cirrhotic patients</brief_summary>
	<brief_title>Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hypertension, Portal</mesh_term>
	<mesh_term>Ifetroban</mesh_term>
	<criteria>liver cirrhosis baseline HVPG &gt;= 8 mmHg and &lt;= 16 mmHg stable liver function enzymes portal or splenic vein thrombosis TIPS or portocaval shunt variceal bleed in last 2 months hemodialysis ChildPugh Score &gt;= 12 MELDNa &gt;= 20 Acute kidney injury, Chronic kidney disease and/or Serum Creatinine &gt;= 2.0 mg/dL current alcohol consumption &gt; 2 drinks per day PLT &lt; 80 x 10^3/uL A change in statin therapy in the last 3 months Current HBV or HCV therapy; or planned initiation of therapy during the treatment period Myocardial infarction within 30 days History of bleeding diathesis or current (within previous 14 days) or planned use of anticoagulant or antiplatelet drugs including aspirin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>